PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

Biotechnology & Medical Research

End-of-day quote OTC Markets 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for PhaseBio Pharmaceuticals, Inc. 0.00% 0.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc. CI
Fourth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc. CI
PhaseBio Pharmaceuticals, Inc. Announces Resignation of Caroline Loewy as Member of the Board of Directors CI
Third Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc. CI
Modified Combined Disclosure Statement Approved on Interim Basis for PhaseBio Pharmaceuticals, Inc. CI
Second Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc. CI
Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc. CI
North American Morning Briefing : Sentiment -2- DJ
North American Morning Briefing : Traders Await -2- DJ
North American Morning Briefing : Stock Futures -3- DJ
First Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc. CI
First Motion for Exclusivity Period Extension Filed by PhaseBio Pharmaceuticals, Inc. CI
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc. CI
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc. CI
Motion for De Minimis Assets Sale Approved for PhaseBio Pharmaceuticals, Inc. CI
Notice of Selection of Auction and Asset Purchase Agreement Filed for Filed by PhaseBio Pharmaceuticals, Inc. CI
Chiesi Farmaceutici S.p.A. cancelled the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab. CI
Notice of Rescheduled Auction Filed by PhaseBio Pharmaceuticals, Inc. CI
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc. CI
Notice of Extention of Bidding Procedures Deadlines Filed by PhaseBio Pharmaceuticals, Inc. CI
Notice of Rescheduled Auction Filed by PhaseBio Pharmaceuticals, Inc. CI
PhaseBio Pharmaceuticals, Inc. Announces Executive Changes CI
Bidding Procedure Approved for PhaseBio Pharmaceuticals, Inc. CI
PhaseBio Pharmaceuticals, Inc. Announces Resignation of John P. Sharp as Chief Financial Officer, Effective November 30, 2022 CI
Final DIP Financing Approved for PhaseBio Pharmaceuticals, Inc. CI
Chart PhaseBio Pharmaceuticals, Inc.
More charts
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The Company is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The Company is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock
  2. Equities
  3. Stock PhaseBio Pharmaceuticals, Inc. - OTC Markets
  4. News PhaseBio Pharmaceuticals, Inc.
  5. PhaseBio Pharmaceuticals : Stifel Adjusts PhaseBio Pharmaceuticals' Price Target to $8 from $11, Keeps Buy Rating